Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) recently announced an agreement with an Israeli energy company that would see about four of its factories in Israel run on natural gas which were earlier being operated from oil and LPG that are considered expensive and polluting. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is 1.89%. On last trading day company shares ended up $50.66. Analysts mean target price for the company is $55.91. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 1.39%.
GlaxoSmithKline plc (ADR) was upgraded by analysts at Panmure Gordon from a “hold” rating to a “buy” rating. GlaxoSmithKline plc (ADR) (NYSE:GSK) shares fell -0.31% in last trading session and ended the day on $55.15. GSK gross Margin is 69.60% and its return on assets is 17.30%.GlaxoSmithKline plc (ADR) (NYSE:GSK) quarterly performance is 0.18%.
Dynavax Technologies Corporation (NASDAQ:DVAX) on 6 may reported a loss of 5 cents per share in the first quarter of 2014, in line with the Zacks Consensus Estimate. The loss reported in the year-ago quarter was 11 cents per share. Dynavax reported revenues of $3.5 million, up 67.8% from the year-ago period and was in line with the Zacks Consensus Estimate. Dynavax Technologies Corporation (NASDAQ:DVAX) shares moved up 2.26% in last trading session and was closed at $1.36, while trading in range of $1.31 – $1.38. Dynavax Technologies Corporation (NASDAQ:DVAX) year to date (YTD) performance is -30.61%.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) announced on 13 may Net loss applicable to common stockholders for the three months ended March 31, 2014 was $9.1 million, or $0.12 per diluted share, compared to a net loss applicable to common stockholders of $4.1 million, or $0.15 per diluted share, for the same period in 2013. There was nominal revenue recognized in the first quarter of 2014 and 2013. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) ended the last trading day at $2.56. Company weekly volatility is calculated as 7.73% and price to cash ratio as 7.18.Idera Pharmaceuticals Inc. (NASDAQ:IDRA) showed a negative weekly performance of -5.54%.
Takeda Pharmaceutical Company Ltd. (ADR) (OTCMKTS:TKPYY) and Takeda Pharmaceuticals U.S.A. Inc. announced that the U.S. Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). On last trading day company shares ended up $22.34.